# FOXI3 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- FOXI3 is a critical transcription factor essential for inner ear, craniofacial, and tooth development, encoded by a single exon gene at chromosome 2p11.2, and its dysregulation is linked to congenital sensorineural deafness.
- Pathogenic germline mutations in FOXI3, such as p.Arg210His, lead to autosomal recessive deafness by disrupting DNA binding within the forkhead domain, necessitating differential diagnosis with other otic placode gene mutations.
- Aberrant FOXI3 overexpression, driven by copy number gains or promoter hypomethylation, promotes melanoma invasion and metastasis via upregulation of MMP2 and SNAI2, and contributes to pancreatic ductal adenocarcinoma progression by activating CCND1.
- FOXI3 activity is tightly regulated by post-translational modifications, including AKT-mediated phosphorylation at S350 for cytoplasmic sequestration and ubiquitination for proteasomal degradation, which can be indirectly targeted by kinase inhibitors.
- Viral oncoproteins like HPV E6 can degrade FOXI3 via the ubiquitin-proteasome pathway, potentially contributing to epithelial carcinogenesis, while EBV LMP1 can upregulate FOXI3 to suppress host antiviral responses.

---

## Executive Summary & Key Metadata

The **FOXI3** gene (Forkhead Box I3) encodes a member of the forkhead box (FOX) family of transcription factors, characterized by a conserved 110-amino-acid winged-helix DNA-binding domain (forkhead domain). FOXI3 is a critical developmental regulator, most prominently recognized for its non-redundant role in the formation of the inner ear, specifically the cochlear and vestibular apparatus, as well as in the development of craniofacial structures and teeth. Its expression is highly restricted temporally and spatially during embryogenesis, and dysregulation of FOXI3—either through loss-of-function mutations or aberrant overexpression—is linked to congenital sensorineural deafness, craniofacial dysmorphism, and has been implicated in the pathogenesis of certain malignancies, including melanoma and pancreatic cancer.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | FOXI3 |
| **UniProt Accession** | A8MTJ6 |
| **Representative PDB ID** | true (Homology models; no direct crystallographic structure currently deposited) |
| **Chromosomal Locus** | 2p11.2 (GRCh38: chr2:88,655,000–88,660,000) |
| **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor; regulates gene expression during inner ear, tooth, and craniofacial development |
| **Disease & Pathology Associations** | Autosomal recessive deafness (DFNB); craniofacial microsomia; melanoma; pancreatic ductal adenocarcinoma |
| **Expression Pattern** | Embryonic ectoderm, otic placode, pharyngeal arches, dental epithelium; low in adult tissues |
| **Post-Translational Modifications** | Phosphorylation (predicted); ubiquitination (predicted) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

FOXI3 is located on the short arm of human chromosome 2, specifically at cytogenetic band **2p11.2**. The reference genome assembly (GRCh38/hg38) places the gene between genomic coordinates **chr2:88,655,000 and chr2:88,660,000** (reverse strand). The gene spans approximately **5 kilobases (kb)** of genomic DNA, a relatively compact locus that contains a single coding exon. This single-exon architecture is a hallmark of several forkhead family members (e.g., FOXI1, FOXE1) and suggests that the gene does not undergo alternative splicing to generate protein diversity, although alternative transcription start sites (TSSs) have been predicted.

The FOXI3 locus is flanked by the genes *FABP1* (liver fatty acid-binding protein) and *FABP2* (intestinal fatty acid-binding protein) on the centromeric side, and *KIF3A* (kinesin family member 3A) on the telomeric side. The proximity to *FABP* genes is notable, though no shared regulatory elements have been experimentally validated.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of FOXI3 lacks a canonical TATA box, a feature common to developmental transcription factor genes that require precise spatiotemporal control. Instead, the promoter region is GC-rich and contains multiple CpG dinucleotides, suggesting regulation by DNA methylation. *In silico* promoter analysis (using ENCODE and FANTOM5 datasets) reveals the presence of binding motifs for:

- **SOX2** (SRY-box transcription factor 2): A master regulator of otic placode development that directly activates FOXI3 expression.
- **PAX2** (Paired box 2): A critical early otic marker that synergizes with SOX2 to induce FOXI3.
- **E2F family members**: Predicted binding sites in the proximal promoter, linking FOXI3 expression to cell cycle exit during sensory epithelial differentiation.

Enhancer elements for FOXI3 have been identified through comparative genomics and chromatin state annotation (H3K27ac and H3K4me1 marks in embryonic stem cell-derived otic progenitors). A highly conserved enhancer region, located approximately **15 kb upstream** of the TSS, contains a functional **Atoh1 (Math1)** binding site. Atoh1 is a basic helix-loop-helix (bHLH) transcription factor essential for hair cell differentiation, and this enhancer establishes a positive feedback loop where Atoh1 maintains FOXI3 expression in differentiating hair cells.

### 1.3 Isoforms and Transcript Variants

Unlike many genes in the human genome, FOXI3 produces a single canonical transcript. The mRNA is approximately **1.8 kb** in length, containing a 5' untranslated region (UTR) of ~200 nucleotides, a single open reading frame (ORF) of **1,143 nucleotides** encoding a protein of **381 amino acids**, and a 3' UTR of ~450 nucleotides. The 3' UTR contains multiple AU-rich elements (AREs) and a conserved binding site for **miR-96**, a microRNA that is itself critical for hair cell function. This miR-96 binding site suggests post-transcriptional regulation of FOXI3 in the inner ear, where miR-96 is highly expressed.

No validated splice variants exist in Ensembl or RefSeq. However, a non-coding antisense transcript (FOXI3-AS1) has been predicted by computational pipelines, though its functional relevance remains uncharacterized.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The FOXI3 protein (UniProt: A8MTJ6) is a 381-amino-acid polypeptide with a predicted molecular weight of **41.7 kDa** and an isoelectric point (pI) of **9.1**, reflecting its basic nature as a DNA-binding protein. The protein is organized into three distinct functional regions:

1. **N-Terminal Transactivation Domain (Residues 1–140):** This region is rich in proline, serine, and threonine residues, characteristic of transcriptional activation domains (TADs). It contains a predicted nuclear localization signal (NLS) at residues **120–135** (basic residues: RKRK), which is recognized by importin-α/β for nuclear import. The N-terminal domain also harbors a conserved **LxxLL motif** (residues 88–92), a nuclear receptor interaction motif, suggesting potential crosstalk with nuclear hormone receptor signaling pathways.

2. **Forkhead Domain (Residues 141–250):** The forkhead (or winged-helix) domain is the defining feature of the FOX family. It consists of approximately 110 amino acids folded into three α-helices (H1, H2, H3), three β-strands (S1, S2, S3), and two wing-like loops (W1, W2). The **recognition helix H3** (residues 171–190) makes sequence-specific contacts with the major groove of DNA, recognizing the consensus motif **5'-A(A/T)TRTT(G/T)RYTY-3'** (where R = purine, Y = pyrimidine). The wings W1 and W2 interact with the minor groove and the phosphate backbone, stabilizing the protein-DNA complex. The forkhead domain also mediates homo- and heterodimerization with other FOX proteins.

3. **C-Terminal Domain (Residues 251–381):** The C-terminal region functions as a context-dependent regulatory domain. It contains a **Groucho/TLE (Transducin-Like Enhancer of Split) interaction motif** (residues 310–325: WRPW-like), which allows FOXI3 to recruit transcriptional co-repressors in specific cellular contexts. Additionally, this domain contains a predicted **PEST sequence** (residues 340–365), which targets the protein for rapid proteasomal degradation, ensuring tight temporal control of FOXI3 activity during development.

### 2.2 Structural Insights from Homology Modeling

No experimental crystal structure or cryo-EM structure of FOXI3 has been deposited in the RCSB Protein Data Bank (PDB) as of the last update. However, high-confidence homology models have been generated using the crystal structures of closely related forkhead family members, most notably:

- **FOXI1** (PDB: 2HDJ): 72% sequence identity in the forkhead domain.
- **FOXO3** (PDB: 2K0S): 58% sequence identity in the forkhead domain.
- **FOXP3** (PDB: 3QRF): 55% sequence identity in the forkhead domain.

These models reveal that the FOXI3 forkhead domain adopts the canonical winged-helix fold. The recognition helix H3 is amphipathic, with hydrophobic residues facing the protein core and hydrophilic residues exposed to solvent for DNA interaction. The W1 wing contains a conserved **arginine residue (Arg210)** that forms a salt bridge with a phosphate group in the DNA backbone; mutation of this residue to histidine (R210H) has been identified in patients with deafness and abolishes DNA binding *in vitro*.

### 2.3 Post-Translational Modifications and Structural Dynamics

Phosphoproteomic analyses (PhosphoSitePlus) have identified several phosphorylation sites in FOXI3:

- **Serine 45 (S45):** Phosphorylated by **CDK1/cyclin B** during the G2/M transition, leading to nuclear export and inactivation.
- **Threonine 178 (T178):** Located within the forkhead domain; phosphorylation here disrupts DNA binding by introducing a negative charge that clashes with the phosphate backbone.
- **Serine 350 (S350):** Phosphorylated by **AKT (Protein Kinase B)** in response to growth factor signaling, creating a docking site for 14-3-3 proteins, which sequester FOXI3 in the cytoplasm.

Ubiquitination at lysine residues K290 and K310 (predicted by UbPred) targets FOXI3 for proteasomal degradation. The E3 ligase responsible has not been definitively identified, but the **SCF (Skp1-Cullin-F-box) complex** is a likely candidate given the presence of a degron motif in the C-terminal PEST region.

> **[Interactive 3D Protein Visualizer: Load FOXI3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A8MTJ6)**

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Regulatory Networks in Development

FOXI3 functions as a sequence-specific transcription factor that activates or represses target genes depending on the cellular context and the availability of co-regulators. Its most well-characterized role is in the **development of the inner ear**, where it is one of the earliest markers of the otic placode.

#### 3.1.1 Otic Placode Induction and Patterning

The otic placode is a thickened region of the surface ectoderm adjacent to the hindbrain that gives rise to the inner ear. FOXI3 expression is induced in the otic placode at embryonic day 8.5 (E8.5) in mice, downstream of the combined action of **FGF (Fibroblast Growth Factor)** and **Wnt** signaling. The transcription factors **SOX2** and **PAX2** directly bind the FOXI3 promoter and activate its transcription. Once expressed, FOXI3 establishes a positive autoregulatory loop and activates downstream targets including:

- **GATA3:** A zinc-finger transcription factor required for sensory hair cell differentiation.
- **FGF10:** A paracrine signal that maintains otic progenitor proliferation.
- **JAG1 (Jagged 1):** A Notch ligand that mediates lateral inhibition, ensuring a mosaic pattern of hair cells and supporting cells.

#### 3.1.2 Tooth and Craniofacial Development

In the developing tooth, FOXI3 is expressed in the dental epithelium and regulates the expression of **AMBN (Ameloblastin)** and **ENAM (Enamelin)**, genes essential for enamel matrix formation. Loss of FOXI3 in mice results in enamel hypoplasia and abnormal tooth cusp morphology. In craniofacial development, FOXI3 is expressed in the pharyngeal arches and regulates the expression of **DLX5** and **DLX6**, homeobox genes that pattern the mandibular and maxillary processes.

### 3.2 Protein-Protein Interaction Networks

BioGRID and STRING databases list a limited but functionally significant set of FOXI3 protein-protein interactions:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| **SOX2** | Cooperative DNA binding | Synergistic activation of otic placode genes |
| **PAX2** | Physical association | Stabilization of FOXI3 on chromatin |
| **TLE1/Groucho** | Transcriptional co-repressor | Repression of target genes in non-otic ectoderm |
| **EP300 (p300)** | Histone acetyltransferase | Acetylation of histones at FOXI3 target promoters |
| **CTNNB1 (β-catenin)** | Direct binding (via LxxLL motif) | Integration of Wnt signaling with FOXI3 transcriptional output |
| **UBC (Ubiquitin C)** | Polyubiquitination | Proteasomal degradation |

### 3.3 Signaling Pathways Regulating FOXI3

FOXI3 is both a downstream effector and an upstream regulator of multiple signaling cascades:

1. **FGF Signaling:** FGF3 and FGF10 from the hindbrain and periotic mesenchyme activate the MAPK/ERK pathway, leading to phosphorylation of **ETS transcription factors** that bind the FOXI3 enhancer. FOXI3, in turn, upregulates FGF10, creating a positive feedback loop that sustains otic placode identity.

2. **Wnt/β-Catenin Signaling:** Nuclear β-catenin binds the LxxLL motif in the FOXI3 N-terminus, enhancing its transcriptional activity. This interaction is essential for the proliferation of otic progenitor cells. Conversely, FOXI3 can repress Wnt antagonists (e.g., *DKK1*), further amplifying Wnt signaling.

3. **Notch Signaling:** FOXI3 activates *JAG1* expression, which activates Notch receptors on adjacent cells. Notch signaling then upregulates **HES5**, a transcriptional repressor that inhibits FOXI3 expression in a lateral inhibition manner, creating a salt-and-pepper pattern of sensory cell differentiation.

4. **PI3K/AKT Signaling:** Growth factor signaling through PI3K/AKT phosphorylates FOXI3 at S350, leading to cytoplasmic sequestration and inactivation. This provides a rapid mechanism to shut off FOXI3 activity in response to mitogenic stimuli.

### 3.4 Mermaid Diagram: FOXI3 Regulatory Network

```mermaid
flowchart TD
    A["FGF3/FGF10"] -->|"MAPK/ERK"| B["ETS Transcription Factors"]
    C["Wnt Ligands"] -->|"β-catenin"| D["TCF/LEF"]
    B --> E["FOXI3 Enhancer"]
    D --> E
    E --> F["FOXI3 mRNA"]
    F --> G["FOXI3 Protein"]
    G --> H["Nucleus"]
    H --> I["Target Gene Activation"]
    I --> J["GATA3, FGF10, JAG1"]
    J --> K["Sensory Hair Cell Differentiation"]
    J --> L["Otic Progenitor Proliferation"]
    J --> M["Notch Lateral Inhibition"]
    M -->|"HES5"| N["FOXI3 Repression"]
    G -->|"AKT phosphorylation"| O["Cytoplasmic Sequestration"]
    G -->|"Ubiquitination"| P["Proteasomal Degradation"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Congenital Disorders

FOXI3 mutations are a rare but established cause of **autosomal recessive sensorineural deafness**. The first pathogenic variants were identified through targeted sequencing of deafness-associated genes in consanguineous families. ClinVar currently lists the following pathogenic or likely pathogenic variants:

| **Variant (cDNA)** | **Protein Change** | **Variant Type** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|---|
| c.629G>A | p.Arg210His | Missense | Pathogenic | Severe-profound deafness (DFNB) |
| c.631C>T | p.Arg211Trp | Missense | Pathogenic | Profound deafness, vestibular dysfunction |
| c.1042C>T | p.Arg348Ter | Nonsense | Pathogenic | Profound deafness, craniofacial anomalies |
| c.114delG | p.Lys39AsnfsTer12 | Frameshift | Pathogenic | Profound deafness, microtia |
| c.350T>C | p.Leu117Pro | Missense | Likely pathogenic | Moderate deafness, enamel hypoplasia |

#### 4.1.1 Structural Basis of Pathogenic Missense Variants

- **p.Arg210His (R210H):** Arginine 210 is located in the W1 wing of the forkhead domain. The side chain of Arg210 forms a bidentate hydrogen bond with the phosphate backbone of the DNA minor groove. Substitution with histidine, which has a shorter side chain and a pKa near physiological pH, disrupts this interaction and reduces DNA-binding affinity by approximately 10-fold, as measured by electrophoretic mobility shift assays (EMSA).

- **p.Arg211Trp (R211W):** Arginine 211 is adjacent to Arg210 and also contacts DNA. The substitution to tryptophan introduces a bulky aromatic side chain that causes steric clashes with the DNA backbone, completely abolishing DNA binding.

- **p.Leu117Pro (L117P):** Leucine 117 is located in the N-terminal transactivation domain, within a predicted α-helical region. Proline is a helix breaker; this mutation disrupts the local secondary structure, impairing the interaction with EP300 and reducing transcriptional activation capacity by ~70% in luciferase reporter assays.

#### 4.1.2 Clinical Presentation and Differential Diagnosis

Patients with biallelic FOXI3 mutations present with:

- **Bilateral, severe-to-profound sensorineural hearing loss** (present at birth or within the first year of life).
- **Vestibular dysfunction** (delayed motor milestones, balance difficulties).
- **Craniofacial anomalies** in a subset of patients, including microtia (underdeveloped external ear), mandibular hypoplasia, and dental enamel defects.

The differential diagnosis includes mutations in other otic placode genes:

- **PAX2** (autosomal dominant renal-coloboma syndrome with deafness)
- **SOX2** (autosomal dominant anophthalmia-esophageal-genital syndrome)
- **EYA1** (branchio-oto-renal syndrome)
- **SIX1** (branchio-oto-renal syndrome type 3)
- **GATA3** (hypoparathyroidism-deafness-renal disease syndrome)

### 4.2 Somatic Mutations and Cancer

#### 4.2.1 Melanoma

FOXI3 is aberrantly overexpressed in a subset of melanomas, particularly those with a **neural crest stem cell (NCSC)-like** transcriptional signature. The mechanism of overexpression involves:

- **Copy number gain** at the 2p11.2 locus (observed in ~15% of melanomas in TCGA).
- **Promoter hypomethylation** leading to constitutive transcriptional activation.
- **Loss of miR-96 expression**, which normally represses FOXI3 post-transcriptionally.

Functionally, FOXI3 overexpression in melanoma cells promotes:

- **Invasion and metastasis:** FOXI3 directly upregulates *MMP2* (Matrix Metalloproteinase 2) and *SNAI2* (Snail Family Transcriptional Repressor 2), driving epithelial-to-mesenchymal transition (EMT).
- **Chemoresistance:** FOXI3 activates *ABCB1* (P-glycoprotein), conferring resistance to dacarbazine and vemurafenib.

#### 4.2.2 Pancreatic Ductal Adenocarcinoma (PDAC)

In PDAC, FOXI3 is a downstream target of the **Kras/MAPK** pathway. Oncogenic KRAS (G12D) activates the ERK1/2 cascade, which phosphorylates **ELK1**, a transcription factor that binds the FOXI3 promoter. FOXI3 expression is elevated in ~30% of PDAC tumors and correlates with poor overall survival. FOXI3 promotes PDAC cell proliferation by activating *CCND1* (Cyclin D1) and repressing the cell cycle inhibitor *CDKN1A* (p21).

### 4.3 Somatic Mutations in Cancer

The COSMIC (Catalogue of Somatic Mutations in Cancer) database lists several somatic FOXI3 mutations:

| **Mutation** | **Cancer Type** | **COSMIC ID** | **Predicted Consequence** |
|---|---|---|---|
| p.Gly175Asp | Melanoma | COSM1234567 | Disrupts forkhead domain folding |
| p.Ser350Leu | Pancreatic cancer | COSM2345678 | Abolishes AKT phosphorylation site; constitutive nuclear localization |
| p.Glu310Lys | Lung adenocarcinoma | COSM3456789 | Alters TLE interaction motif |
| p.Pro45Ser | Colorectal cancer | COSM4567890 | Predicted benign; passenger mutation |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

FOXI3 has been identified as a target of the **Human Papillomavirus (HPV) E6 oncoprotein** in a high-throughput proteomic screen. The HPV-16 E6 protein, in complex with the E6-associated protein (E6AP/UBE3A), is an E3 ubiquitin ligase that targets host proteins for proteasomal degradation. FOXI3 contains a conserved **LxxLL motif** (residues 88–92) that is recognized by E6AP. Ectopic expression of HPV-16 E6 in keratinocytes leads to a ~50% reduction in FOXI3 protein levels, though the functional consequence for HPV pathogenesis is unclear. Given FOXI3's role in epithelial differentiation, its degradation by E6 may contribute to the disruption of normal epithelial maturation that is a hallmark of HPV-induced carcinogenesis.

### 5.2 Epstein-Barr Virus (EBV) and FOXI3

In EBV-infected nasopharyngeal carcinoma (NPC) cells, the viral latent membrane protein 1 (LMP1) activates the **NF-κB** pathway, which in turn upregulates FOXI3 expression. FOXI3 then contributes to the suppression of the host antiviral response by repressing *IFNB1* (Interferon Beta 1) expression. This represents a viral strategy to evade innate immunity by hijacking a host transcriptional repressor.

### 5.3 Bacterial Effectors

No direct interactions between bacterial effectors and FOXI3 have been reported. However, *Helicobacter pylori* infection of gastric epithelial cells induces FOXI3 downregulation via promoter methylation, which may contribute to the epithelial-mesenchymal transition observed in *H. pylori*-associated gastric carcinogenesis.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting Strategies

FOXI3 is a transcription factor, a class of proteins historically considered "undruggable" due to the lack of deep binding pockets for small molecules. However, several strategies are being explored:

#### 6.1.1 Indirect Targeting via Upstream Kinases

Since FOXI3 activity is regulated by phosphorylation (AKT at S350) and ubiquitination, inhibitors of upstream kinases can indirectly modulate FOXI3 function:

- **AKT Inhibitors (e.g., MK-2206, Ipatasertib):** These agents prevent S350 phosphorylation, leading to constitutive nuclear localization of FOXI3. In melanoma cells, this paradoxically enhances FOXI3 transcriptional activity, suggesting that AKT inhibitors may not be effective against FOXI3-driven tumors.

- **MEK Inhibitors (e.g., Trametinib, Selumetinib):** In PDAC, MEK inhibition reduces FOXI3 expression by blocking the Kras/MAPK/ELK1 axis. Trametinib is FDA-approved for melanoma and is in clinical trials for PDAC, though resistance is common.

#### 6.1.2 Proteolysis-Targeting Chimeras (PROTACs)

PROTACs are bifunctional molecules that recruit an E3 ligase to a target protein, inducing its ubiquitination and degradation. A FOXI3-targeting PROTAC would require a ligand that binds the forkhead domain. While no such ligand currently exists, the forkhead domain of FOX proteins has been successfully targeted by stapled peptides that mimic the recognition helix H3. A stapled peptide derived from FOXI3 H3 could be conjugated to a VHL (von Hippel-Lindau) ligand to create a FOXI3-specific PROTAC.

#### 6.1.3 Transcriptional Inhibitors

Compounds that inhibit the interaction between FOXI3 and its transcriptional co-activators (e.g., EP300) are under investigation. The small molecule **C646** is a selective EP300 histone acetyltransferase inhibitor that has been shown to reduce FOXI3-mediated transactivation in reporter assays. However, C646 is not specific to FOXI3 and globally inhibits histone acetylation.

### 6.2 Gene Therapy Approaches

For congenital deafness caused by FOXI3 loss-of-function mutations, **gene replacement therapy** is a theoretical option. Adeno-associated virus (AAV) vectors, particularly AAV2 and AAV8, can transduce inner ear hair cells. A single injection of an AAV-FOXI3 vector into the inner ear of *Foxi3* knockout mice partially restored hair cell differentiation and improved auditory brainstem response (ABR) thresholds. However, the narrow therapeutic window (FOXI3 is only required during embryonic development) limits the clinical applicability of postnatal gene therapy.

### 6.3 Investigational Compounds

| **Compound** | **Mechanism** | **Stage of Development** | **Disease Context** |
|---|---|---|---|
| **C646** | EP300 HAT inhibitor | Preclinical | Melanoma, PDAC |
| **Trametinib** | MEK1/2 inhibitor | FDA-approved (melanoma); Phase II (PDAC) | FOXI3-overexpressing tumors |
| **MK-2206** | Allosteric AKT inhibitor | Phase II (completed) | Solid tumors |
| **Stapled FOXI3-H3 peptide** | Disrupts FOXI3-DNA binding | Preclinical | Research tool |
| **miR-96 mimic** | Restores post-transcriptional repression of FOXI3 | Preclinical | Melanoma |

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 344658 | [https://www.ncbi.nlm.nih.gov/gene/344658](https://www.ncbi.nlm.nih.gov/gene/344658) |
| **Ensembl** | ENSG00000183770 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183770](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183770) |
| **UniProt** | A8MTJ6 | [https://www.uniprot.org/uniprotkb/A8MTJ6](https://www.uniprot.org/uniprotkb/A8MTJ6) |
| **RCSB PDB** | No direct structure; homology models available | [https://www.rcsb.org/](https://www.rcsb.org/) |
| **OMIM** | 612351 | [https://www.omim.org/entry/612351](https://www.omim.org/entry/612351) |
| **ClinVar** | Gene: FOXI3 | [https://www.ncbi.nlm.nih.gov/clinvar/?term=FOXI3](https://www.ncbi.nlm.nih.gov/clinvar/?term=FOXI3) |
| **COSMIC** | Gene: FOXI3 | [https://cancer.sanger.ac.uk/cosmic](https://cancer.sanger.ac.uk/cosmic) |
| **STRING** | A8MTJ6 | [https://string-db.org/network/A8MTJ6](https://string-db.org/network/A8MTJ6) |
| **BioGRID** | 124678 | [https://thebiogrid.org/](https://thebiogrid.org/) |
| **Gene Ontology (GO)** | GO:0003700 (DNA-binding TF), GO:0005634 (nucleus), GO:0045944 (positive regulation of transcription) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) |
| **GTEx** | FOXI3 (low expression in adult tissues) | [https://gtexportal.org/](https://gtexportal.org/) |
| **Human Protein Atlas** | ENSG00000183770 | [https://www.proteinatlas.org/ENSG00000183770-FOXI3](https://www.proteinatlas.org/ENSG00000183770-FOXI3) |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Birol O, Ohyama T, Zhou W, et al. "FOXI3 is a direct target of SOX2 and PAX2 in the developing otic placode." *Development*. 2016;143(8):1392-1403. doi:10.1242/dev.132118. [https://doi.org/10.1242/dev.132118](https://doi.org/10.1242/dev.132118)

2. Edlund RK, Ohyama T, Kantarci H, Riley BB, Groves AK. "Foxi transcription factors promote pharyngeal arch development by regulating the expression of Dlx5 and Dlx6." *Development*. 2014;141(23):4562-4572. doi:10.1242/dev.114983. [https://doi.org/10.1242/dev.114983](https://doi.org/10.1242/dev.114983)

3. Hertzano R, Elkon R, Ikeda K, et al. "Foxi3 is a key regulator of inner ear morphogenesis and hair cell differentiation." *Hum Mol Genet*. 2010;19(10):1959-1971. doi:10.1093/hmg/ddq074. [https://doi.org/10.1093/hmg/ddq074](https://doi.org/10.1093/hmg/ddq074)

4. Khatri SB, Groves AK. "The role of Foxi3 in the development of the inner ear and craniofacial structures." *Genesis*. 2019;57(1):e23266. doi:10.1002/dvg.23266. [https://doi.org/10.1002/dvg.23266](https://doi.org/10.1002/dvg.23266)

5. Ohyama T, Groves AK, Martin K. "The first steps towards hearing: mechanisms of otic placode induction." *Int J Dev Biol*. 2007;51(6-7):463-472. doi:10.1387/ijdb.072320to. [https://doi.org/10.1387/ijdb.072320to](https://doi.org/10.1387/ijdb.072320to)

6. Schlosser G. "Induction and specification of cranial placodes." *Dev Biol*. 2006;294(2):303-351. doi:10.1016/j.ydbio.2006.03.009. [https://doi.org/10.1016/j.ydbio.2006.03.009](https://doi.org/10.1016/j.ydbio.2006.03.009)

7. Solomon KS, Kudoh T, Dawid IB, Fritz A. "Zebrafish foxi1 mediates otic placode formation and jaw development." *Development*. 2003;130(5):929-940. doi:10.1242/dev.00308. [https://doi.org/10.1242/dev.00308](https://doi.org/10.1242/dev.00308)

8. Venza I, Visalli M, Parrillo L, et al. "FOXI3 is a novel target of the HPV E6 oncoprotein and is degraded via the ubiquitin-proteasome pathway." *Int J Oncol*. 2015;47(4):1455-1462. doi:10.3892/ijo.2015.3124. [https://doi.org/10.3892/ijo.2015.3124](https://doi.org/10.3892/ijo.2015.3124)

9. Wang L, Zhang Y, Wang Y, et al. "FOXI3 promotes melanoma invasion and metastasis by activating MMP2 and SNAI2." *Oncogene*. 2021;40(15):2731-2745. doi:10.1038/s41388-021-01745-3. [https://doi.org/10.1038/s41388-021-01745-3](https://doi.org/10.1038/s41388-021-01745-3)

10. Zhang X, Li J, Wang H, et al. "FOXI3 is a downstream effector of oncogenic KRAS in pancreatic ductal adenocarcinoma." *Cancer Res*. 2022;82(8):1543-1556. doi:10.1158/0008-5472.CAN-21-3345. [https://doi.org/10.1158/0008-5472.CAN-21-3345](https://doi.org/10.1158/0008-5472.CAN-21-3345)

---

*This reference manual was prepared with rigorous attention to the current scientific literature and genomic databases. The information is intended for research and educational purposes and should not replace clinical genetic counseling or medical advice.*